Greenwich LifeSciences Business Summary

Greenwich LifeSciences, Inc. (GLSI) is a clinical-stage biopharmaceutical company primarily focused on the development and commercialization of GLSI-100 (GP2 + GM-CSF), a proprietary immunotherapy designed to prevent breast cancer recurrence in HER2/neu-positive patients. The company currently generates no product revenue, operating as a pre-revenue entity that funds its clinical operations through equity financing, including an active At-The-Market (ATM) vehicle. Its business model is centered on the successful execution of the global Phase III FLAMINGO-01 trial, with the ultimate goal of securing a Biologics License Application (BLA) and generating revenue through direct commercial sales or strategic licensing agreements. In the competitive landscape of HER2-targeted therapies, Greenwich LifeSciences competes with Sellas Life Sciences, Precigen, and established oncology leaders such as Roche and AstraZeneca. GLSI-100 distinguishes itself by targeting the adjuvant setting post-standard-of-care, aiming to provide a 100% disease-free survival rate in high-risk patients, a significant improvement over the 50% recurrence reduction typically achieved by existing monoclonal antibodies like Herceptin and Kadcyla. The leadership team is led by Snehal Patel, who serves as the Chief Executive Officer, Chief Financial Officer, and a Director. Patel brings over 30 years of experience in healthcare management and investment banking, with a pedigree that includes roles at JP Morgan Chase and Bayer Corporation, and degrees from MIT and the University of Chicago. The clinical strategy is overseen by Chief Medical Officer and Director Frank Joseph Daugherty, M.D., a veteran with over 35 years of experience in managing biomedical projects at firms such as Eleos and ConAgra. The company was founded by Eric Rothe, who remains an Independent Director, while the Board is chaired by David McWilliams, an industry veteran with 40 years of experience in biopharmaceutical development. Notable for its high insider alignment, CEO Snehal Patel remains the largest shareholder with an approximate 40% stake, supported by institutional investors including Geode Capital Management, Vanguard Group, and State Street Corporation.